HSE greenlights Skyclarys treatment for Friedreich's Ataxia sufferers
The Health Service Executive has authorised funding for a new therapy targeting a rare neurological condition. This decision follows revised pricing terms from Biogen, addressing significant patient needs despite clinical evidence limitations.
The Health Service Executive's Senior Management Team has now approved reimbursement for Skyclarys, a treatment for Friedreich's Ataxia, after Biogen presented a substantially improved financial proposal. This move comes following intensive negotiations that led to a revised commercial arrangement distinct from earlier evaluations.
The SMT acknowledged the drug's limited efficacy and persistent high costs but recognised the critical unmet need for patients with this devastating condition, where no alternative treatments exist. The decision also considered the Health (Pricing and Supply of Medical Goods) Act 2013 and potential weaknesses in clinical evidence.
Ongoing discussions with Biogen will finalise administrative arrangements to enable prompt reimbursement. Patients and clinicians can expect the process to advance swiftly, with both parties committed to expediting implementation of this new healthcare provision.